Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C84217
http://purl.obolibrary.org/obo/NCIT_C84217
Preferred Name

Tocilizumab
Definitions
A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.
prefLabel
Tocilizumab
label
Tocilizumab
CHEBI_ID
CHEBI:64360
PDQ_Closed_Trial_Search_ID
713832
code
C84217
Has_Target
prefixIRI
NCIT:C84217
in_subset
Display_Name
Tocilizumab
Preferred_Name
Tocilizumab
FDA_UNII_Code
I031V2H011
Contributing_Source
CTRP
FDA
Maps_To
Tocilizumab
CAS_Registry
375823-41-9
NCI_Drug_Dictionary_ID
713832
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
713832
Accepted_Therapeutic_Use_For
Treatment of COVID-19-emergency use authorization (EUA).
Semantic_Type
Pharmacologic Substance
UMLS_CUI
C1609165
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display